Developer docs
API playgroundTry for free, no card

Search company profiles

Tricares

Full company profile

uuid00021nc

Namestring
Tricares
Legal namestring
TRiCares SAS
Websiteurl
tricares.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

TRiCares SAS is a privately-held medical device company headquartered in Paris, France, with operations in Aschheim/Munich (Germany), St. Louis Park, Minnesota (USA), and Brazil. Founded around 2013-2015, the company is developing the Topaz transcatheter tricuspid valve replacement (TTVR) system, a Class III catheter-based device designed to treat severe tricuspid regurgitation (TR) without open-heart surgery. TR is described as the "forgotten valve" because 99% of patients are deemed ineligible for surgical intervention given 10-35% operative mortality, leaving median survival of only 2.2 years. The Topaz system targets an estimated 1.6 million US and 3 million European TR patients and a TTVR device market projected to reach $3.7 billion by 2035.

The Topaz system comprises a dual-stent biological heart valve prosthesis (available in TC-M 45mm and TC-L 55mm sizes, covering an estimated 85-90% of TR anatomies) and a steerable catheter-based delivery system supporting transfemoral venous and transjugular access. The outer stent anchors on native tricuspid leaflets and adapts to patient anatomy, while the inner stent scaffolds a three-leaflet pericardial tissue valve; the system is designed to flex with every heartbeat and minimize impact on cardiac conduction pathways. First-in-human implantations were performed in France in 2021, with the technology now evaluated across the TRICURE FIH study, the 80-patient EU Pivotal trial (Belgium, Denmark, France, Germany, Spain, Switzerland), and the US Early Feasibility Study; FDA IDE for the US Pivotal Trial was secured in April 2026. More than 60 implantations have been performed across Europe and Canada.

TRiCares' business model is pre-commercial: revenue will be generated through direct hospital sales of the Topaz system to structural heart centers under a hardware sales model once regulatory approvals are obtained. The company has raised approximately €73M in equity (Series B €22M in 2018, Series C €51M in 2022, Series D $50M in 2024) plus a €20M non-dilutive EIB loan in 2026, from a syndicate including 415 Capital, Andera Partners, Bayern Kapital, BioMed Partners, Credit Mutuel Innovation, GO Capital, Karista, Wellington Partners, and an unnamed strategic investor. Leadership comprises experienced structural-heart veterans, including CEO Ahmed Elmouelhi (ex-AtriCure, Medtronic, AGA Medical) and COO Laura Ghione (ex-Sorin/LivaNova).

Short descriptiontext

TRiCares is a Paris-based, privately-held medical device company developing the Topaz transcatheter tricuspid valve replacement system to treat severe tricuspid regurgitation without open-heart surgery, currently in clinical trials across Europe, Canada, and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAschheim, Germany
HQ citystring
Aschheim
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter valve replacement, tricuspid regurgitation treatment, structural heart devices, catheter-based cardiac devices, minimally invasive cardiology
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Structural Heart Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Topaz Tricuspid Valve Replacement System Sales
TypeHardware Sales
Description

Once regulatory approvals are obtained (FDA and CE marking), TRiCares will generate revenue from the sale of its Topaz transcatheter tricuspid valve replacement system to hospitals and cardiac centers. The system includes the valve prosthesis and the catheter-based implantation system. Revenue will be generated through direct hospital sales as a Class III medical device.

tricares.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Topaz
Description

Transcatheter Tricuspid Valve Replacement (TTVR) System - a self-expanding dual-stent biological heart valve prosthesis designed to eliminate tricuspid regurgitation through a minimally invasive femoral vein approach.

tricares.com
Core offering1 text field

TRiCares develops and manufactures the Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System, a catheter-based medical device designed to treat severe tricuspid regurgitation through a minimally invasive transfemoral venous approach without open-heart surgery. The system comprises a self-expanding biological heart valve prosthesis with a unique dual-stent design and a steerable delivery system, available in two sizes (TC-M 45mm and TC-L 55mm) that together address 85-90% of TR patients. The product is sold as a Class III medical device to hospitals and cardiac centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 35-minute average implantation time in first-in-human trial
+6 more records
Product overview1 text field

TRiCares offers the Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System as its core product portfolio. The system consists of the Topaz Heart Valve Prosthesis (with TC-M 45mm and TC-L 55mm valve sizes) and the Topaz Implantation System (comprising a steerable sheath and delivery system). The dual-stent valve prosthesis is inserted via femoral vein access and is designed specifically for the tricuspid valve position, flexing with each heartbeat to eliminate tricuspid regurgitation without requiring open-heart surgery.

Product and service2 records
1Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System
CategoryStructural Heart Medical Devices
Description

A minimally invasive transcatheter tricuspid valve replacement system designed to eliminate tricuspid regurgitation through transfemoral venous access without open-heart surgery. The system uses a unique dual stent design that flexes with every heartbeat and is sold as a Class III medical device to hospitals and cardiac centers for treating patients with severe tricuspid regurgitation.

2Topaz TC-L 55mm Valve
CategoryStructural Heart Medical Devices
Description

A larger valve size in the Topaz portfolio introduced to expand treatment to a broader TR patient population, enabling treatment of 85-90% of all patients presenting with tricuspid regurgitation diagnosis.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global structural heart leader with PASCAL transcatheter tricuspid repair system and dominant TAVR franchise. Operates in the same tricuspid disease space as TRiCares with overlapping structural heart center customer base, though via repair rather than replacement.

2Venus Medtech (Cardiovalve)
TypeDirect peer
Description

Chinese structural heart company that acquired Cardiovalve, one of the closest direct TTVR peers to TRiCares. Competing transcatheter tricuspid valve replacement technology targeting the same patient population and clinical indications.

3Abbott
TypeBroad incumbent
Description

Diversified medtech with the TriClip transcatheter tricuspid repair system as well as structural heart products across mitral and aortic. Targets the same tricuspid regurgitation patient population and structural heart center accounts as TRiCares.

TypeBroad incumbent
Description

Global structural heart incumbent with extensive TAVR and mitral programs and a deep structural heart center salesforce. While Medtronic does not yet have a dedicated TTVR product, it represents a potential strategic acquirer and structural-heart channel competitor.

TypeDirect peer
Description

Emerging Irish medical device company developing a transcatheter tricuspid valve coaptation/Replacement solution. Direct TTVR peer in early-stage development targeting the same underserved tricuspid regurgitation market.

6LuX-Valve
TypeDirect peer
Description

China-based developer of transcatheter tricuspid valve replacement technology. Direct competitor in dedicated TTVR with comparable clinical-stage positioning and target patient population.

TypeBroad incumbent
Description

Diversified structural heart player with transcatheter aortic and mitral programs and growing interest in tricuspid. Potential strategic acquirer and broader competitive presence in the same hospital accounts.

TypeEmerging player
Description

Israeli medical device company developing transcatheter solutions for tricuspid regurgitation. Adjacent competitor addressing overlapping structural heart and tricuspid disease market.

TypeEmerging player
Description

Early-stage transcatheter heart valve company with mitral and tricuspid programs. Comparable European medtech with similar structural-heart clinical-stage profile and target customer base.

TypeDirect peer
Description

Early-stage developer of transcatheter tricuspid valve replacement technologies addressing the same patient population as TRiCares. Direct TTVR peer in clinical development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tricares

Structural Heart Medical Devicestricares.com

TRiCares is a Paris-based, privately-held medical device company developing the Topaz transcatheter tricuspid valve replacement system to treat severe tricuspid regurgitation without open-heart surgery, currently in clinical trials across Europe, Canada, and the US.

What Tricares does

TRiCares SAS is a privately-held medical device company headquartered in Paris, France, with operations in Aschheim/Munich (Germany), St. Louis Park, Minnesota (USA), and Brazil. Founded around 2013-2015, the company is developing the Topaz transcatheter tricuspid valve replacement (TTVR) system, a Class III catheter-based device designed to treat severe tricuspid regurgitation (TR) without open-heart surgery. TR is described as the "forgotten valve" because 99% of patients are deemed ineligible for surgical intervention given 10-35% operative mortality, leaving median survival of only 2.2 years. The Topaz system targets an estimated 1.6 million US and 3 million European TR patients and a TTVR device market projected to reach $3.7 billion by 2035.

The Topaz system comprises a dual-stent biological heart valve prosthesis (available in TC-M 45mm and TC-L 55mm sizes, covering an estimated 85-90% of TR anatomies) and a steerable catheter-based delivery system supporting transfemoral venous and transjugular access. The outer stent anchors on native tricuspid leaflets and adapts to patient anatomy, while the inner stent scaffolds a three-leaflet pericardial tissue valve; the system is designed to flex with every heartbeat and minimize impact on cardiac conduction pathways. First-in-human implantations were performed in France in 2021, with the technology now evaluated across the TRICURE FIH study, the 80-patient EU Pivotal trial (Belgium, Denmark, France, Germany, Spain, Switzerland), and the US Early Feasibility Study; FDA IDE for the US Pivotal Trial was secured in April 2026. More than 60 implantations have been performed across Europe and Canada.

TRiCares' business model is pre-commercial: revenue will be generated through direct hospital sales of the Topaz system to structural heart centers under a hardware sales model once regulatory approvals are obtained. The company has raised approximately €73M in equity (Series B €22M in 2018, Series C €51M in 2022, Series D $50M in 2024) plus a €20M non-dilutive EIB loan in 2026, from a syndicate including 415 Capital, Andera Partners, Bayern Kapital, BioMed Partners, Credit Mutuel Innovation, GO Capital, Karista, Wellington Partners, and an unnamed strategic investor. Leadership comprises experienced structural-heart veterans, including CEO Ahmed Elmouelhi (ex-AtriCure, Medtronic, AGA Medical) and COO Laura Ghione (ex-Sorin/LivaNova).

Tricares firmographics

Firmographics
Name
Tricares
Legal name
TRiCares SAS
Website
https://tricares.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
TRiCares is a Paris-based, privately-held medical device company developing the Topaz transcatheter tricuspid valve replacement system to treat severe tricuspid regurgitation without open-heart surgery, currently in clinical trials across Europe, Canada, and the US.
Ownership category
akta.pro rank

Tricares industry classification

Industry
Product category
Structural Heart Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter valve replacement
  • Tricuspid regurgitation treatment
  • Structural heart devices
  • Catheter-based cardiac devices
  • Minimally invasive cardiology

Where Tricares is headquartered

Location

Headquarters

HQ city
Aschheim
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

Tricares business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Topaz Tricuspid Valve Replacement System Sales: Once regulatory approvals are obtained (FDA and CE marking), TRiCares will generate revenue from the sale of its Topaz transcatheter tricuspid valve replacement system to hospitals and cardiac centers. The system includes the valve prosthesis and the catheter-based implantation system. Revenue will be generated through direct hospital sales as a Class III medical device.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Tricares product offering

Product offering

Core offering

TRiCares develops and manufactures the Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System, a catheter-based medical device designed to treat severe tricuspid regurgitation through a minimally invasive transfemoral venous approach without open-heart surgery. The system comprises a self-expanding biological heart valve prosthesis with a unique dual-stent design and a steerable delivery system, available in two sizes (TC-M 45mm and TC-L 55mm) that together address 85-90% of TR patients. The product is sold as a Class III medical device to hospitals and cardiac centers.

Product overview

TRiCares offers the Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System as its core product portfolio. The system consists of the Topaz Heart Valve Prosthesis (with TC-M 45mm and TC-L 55mm valve sizes) and the Topaz Implantation System (comprising a steerable sheath and delivery system). The dual-stent valve prosthesis is inserted via femoral vein access and is designed specifically for the tricuspid valve position, flexing with each heartbeat to eliminate tricuspid regurgitation without requiring open-heart surgery.

Differentiator

Problem solved

Functional benefit

Brands

  • Topaz: Transcatheter Tricuspid Valve Replacement (TTVR) System - a self-expanding dual-stent biological heart valve prosthesis designed to eliminate tricuspid regurgitation through a minimally invasive femoral vein approach.

Products and services

  • Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System A minimally invasive transcatheter tricuspid valve replacement system designed to eliminate tricuspid regurgitation through transfemoral venous access without open-heart surgery. The system uses a unique dual stent design that flexes with every heartbeat and is sold as a Class III medical device to hospitals and cardiac centers for treating patients with severe tricuspid regurgitation.
  • Topaz TC-L 55mm Valve A larger valve size in the Topaz portfolio introduced to expand treatment to a broader TR patient population, enabling treatment of 85-90% of all patients presenting with tricuspid regurgitation diagnosis.

Quantifiable outcome

  • 35-minute average implantation time in first-in-human trial
  • +6 more outcomes

Companies that use Tricares

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles1 record

Tricares technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Tricares partnerships and signals

Strategic signal

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Tricares competitors and assessment

Company assessment

Broad incumbents

  • Edwards Lifesciences: Global structural heart leader with PASCAL transcatheter tricuspid repair system and dominant TAVR franchise. Operates in the same tricuspid disease space as TRiCares with overlapping structural heart center customer base, though via repair rather than replacement.
  • Abbott: Diversified medtech with the TriClip transcatheter tricuspid repair system as well as structural heart products across mitral and aortic. Targets the same tricuspid regurgitation patient population and structural heart center accounts as TRiCares.
  • Medtronic: Global structural heart incumbent with extensive TAVR and mitral programs and a deep structural heart center salesforce. While Medtronic does not yet have a dedicated TTVR product, it represents a potential strategic acquirer and structural-heart channel competitor.
  • Boston Scientific: Diversified structural heart player with transcatheter aortic and mitral programs and growing interest in tricuspid. Potential strategic acquirer and broader competitive presence in the same hospital accounts.

Direct peers

  • Venus Medtech (Cardiovalve): Chinese structural heart company that acquired Cardiovalve, one of the closest direct TTVR peers to TRiCares. Competing transcatheter tricuspid valve replacement technology targeting the same patient population and clinical indications.
  • CroíValve: Emerging Irish medical device company developing a transcatheter tricuspid valve coaptation/Replacement solution. Direct TTVR peer in early-stage development targeting the same underserved tricuspid regurgitation market.
  • LuX-Valve: China-based developer of transcatheter tricuspid valve replacement technology. Direct competitor in dedicated TTVR with comparable clinical-stage positioning and target patient population.
  • NaviGate Cardiac Structures: Early-stage developer of transcatheter tricuspid valve replacement technologies addressing the same patient population as TRiCares. Direct TTVR peer in clinical development.

Emerging players

  • Innoventric: Israeli medical device company developing transcatheter solutions for tricuspid regurgitation. Adjacent competitor addressing overlapping structural heart and tricuspid disease market.
  • HighLife Medical: Early-stage transcatheter heart valve company with mitral and tricuspid programs. Comparable European medtech with similar structural-heart clinical-stage profile and target customer base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Tricares social profiles

Digital presence

Tricares financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tricares leadership team

Management profile

Number of profiles

Profiles8 records

Tricares funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tricares M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tricares

What does Tricares do?

TRiCares develops and manufactures the Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System, a catheter-based medical device designed to treat severe tricuspid regurgitation through a minimally invasive transfemoral venous approach without open-heart surgery. The system comprises a self-expanding biological heart valve prosthesis with a unique dual-stent design and a steerable delivery system, available in two sizes (TC-M 45mm and TC-L 55mm) that together address 85-90% of TR patients. The product is sold as a Class III medical device to hospitals and cardiac centers.

Is Tricares a public or private company?

Tricares is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tricares founded?

Tricares was founded in 2015. It employs 51 to 100 people.

Where is Tricares based?

Tricares is headquartered in Aschheim, Germany, in the Europe region.

How does Tricares make money?

One revenue line is on record: topaz Tricuspid Valve Replacement System Sales.

Who are Tricares's main competitors?

Broad incumbents on record are Edwards Lifesciences, Abbott, Medtronic and Boston Scientific. Direct peers are Venus Medtech (Cardiovalve), CroíValve, LuX-Valve and NaviGate Cardiac Structures. Emerging players are Innoventric and HighLife Medical.

Does Tricares have an API?

No public API is recorded for Tricares.

What industry is Tricares in?

Tricares's product category is Structural Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkTRiCares begins US IDE pivotal trial of TTVR systemTRiCares SAS has enrolled and treated the first patient in its TRICURE US IDE pivotal study of the Topaz transcatheter tricuspid valve replacement (TTVR) system at Piedmont Heart Institute in Atlanta, Georgia. The trial is the first randomized controlled study to directly compare the investigational Topaz system head-to-head against the commercially available Edwards EVOQUE TTVR system. The multi-centre global prospective trial will evaluate safety and effectiveness in patients with severe or greater tricuspid regurgitation across up to 75 centres in Canada, the US, and several European countries.MassDeviceTriCares kicks off IDE study for tricuspid valve replacement systemTriCares has enrolled the first patient in its TRICURE US FDA investigational device exemption (IDE) study for the Topaz transcatheter tricuspid valve replacement (TTVR) system, marking the start of the first randomized controlled study comparing an investigational TTVR system directly against the commercially available Edwards Evoque TTVR system. The company, headquartered in Munich with operations in Paris and Minneapolis, will conduct the pivotal trial at up to 75 sites across the U.S., Canada, and Europe, with the first enrollment occurring at Piedmont Heart Institute in Atlanta. TriCares aims to establish Topaz as a preferred treatment option for tricuspid regurgitation patients globally, building on favorable early clinical results showing a fast, easy-to-use procedure with few pacemaker implant requirements.GlobeNewswireTRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement SystemTRiCares SAS announced the enrollment of the first patient in its TRICURE US IDE pivotal study evaluating the Topaz Transcatheter Tricuspid Valve Replacement system, conducted at Piedmont Heart Institute in Atlanta, Georgia. The study represents the first randomized controlled trial to directly compare an investigational TTVR device against the commercially available Edwards EVOQUE TTVR system in a head-to-head evaluation. The global multicenter study will enroll patients across the US, Canada, and several European countries at up to 75 sites, marking a significant milestone in advancing treatment for tricuspid regurgitation.Clinical Trials ArenaTRiCares gains FDA IDE to initiate tricuspid regurgitation treatment pivotal trialTRiCares has received FDA investigational device exemption (IDE) approval to initiate a pivotal trial of its Topaz transcatheter tricuspid valve replacement (TTVR) system for treating tricuspid regurgitation, a condition affecting approximately 1.5 million people in the US. The pivotal trial will build on an early feasibility study that began in January 2025, with first-in-human data from May 2025 showing improvements in 20 patients. Edwards Lifesciences' EVOQUE currently remains the only TTVR system approved in the US, while Abbott's TriClip is approved for valve repair rather than replacement.Pulse 2.0TRiCares: Up To €20 Million EIB Loan Secured To Advance Topaz Tricuspid Valve Replacement TrialsTRiCares SAS has signed a loan agreement for up to €20 million in non-dilutive financing with the European Investment Bank to support research, development, and clinical trials for its Topaz Transfemoral Tricuspid Heart Valve Replacement system. The funding will advance the company's European pivotal study enrolling 80 patients across Belgium, Denmark, France, Germany, Spain, and Switzerland, as well as its U.S. TRICURE early feasibility study. TRiCares is working toward FDA approval and CE marking for the device, which uses a dual stent valve design to replace the tricuspid valve without open-heart surgery.FinSMEsTRiCares To Receive €20M Loan From European Investment BankTRiCares, an Aschheim, Germany-based medical device company developing the Topaz minimally invasive tricuspid valve replacement system, has secured a €20 million non-dilutive loan from the European Investment Bank. The funding will support expansion of operations and development efforts for the Topaz system, which uses a dual stent design to enable transfemoral and transjugular delivery, eliminating the need for high-risk open-heart surgery. The company maintains offices in France, Germany, the United States, and Brazil.GlobeNewswireTRiCares Enters into €20 million Loan Agreement with the European Investment BankTRiCares secured up to €20 million in non-dilutive financing from the European Investment Bank. The funds will support research, development, and clinical studies of its Topaz tricuspid valve replacement system, including a European pivotal study enrolling 80 patients and a US early feasibility study with 15 patients.GlobeNewswireTRiCares Enters into €20 million Loan Agreement with the European Investment BankTRiCares SAS has secured up to €20 million in non-dilutive financing from the European Investment Bank to support its research, development, and innovation activities for the Topaz Transfemoral Tricuspid Heart Valve Replacement system. The funding will advance ongoing clinical studies, including a European pivotal study enrolling 80 patients across Belgium, Denmark, France, Germany, and Spain, as well as a US Early Feasibility Study at 8 sites with 15 patients. CEO Ahmed Elmouhi described the EIB loan as validation of the company's approach and stated plans to begin an IDE pivotal trial toward FDA approval and CE marking.GlobeNewswireTRiCares presents promising First-In-Human Topaz data at EuroPCR 2025TRiCares presented first-in-human data for its Topaz transcatheter tricuspid valve replacement system at EuroPCR 2025, showing near-complete elimination of tricuspid regurgitation in 20 patients. Zero permanent pacemakers were required, and the procedure averaged 35 minutes. The results will inform ongoing European and U.S. trials.GlobeNewswireTRiCares Announces First Topaz Implantations in US Early Feasibility StudyTRiCares announced the first Topaz tricuspid valve implantations in the US Early Feasibility Study, with procedures performed at Piedmont Heart Institute and MUSC. The study enrolls up to 15 patients across 8 sites, and the company is also advancing its European pivotal study.